Skip to content

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Journal
LUNG CANCER162 · pp.9 · 2021
Citation
Web of Science 28Scopus 27
FWCI (Scopus)
1.55
JCR IF
JCR 2020 5.705
ISSN
0169-5002

Authors

  1. Popat, SanjayFirst authorCorresponding authorRoyal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, 203 Fulham Rd, London SW3 6JJ, England
  2. Jung, Hyun AeSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
  3. Lee, Shin YupKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
  4. Hochmair, Maximilian J.Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria
  5. Lee, Seung HyeunKyung Hee Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Seoul, South Korea
  6. Escriu, CarlesClatterbridge Canc Ctr, Wirral, Merseyside, England
  7. Lee, Min KiPusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea
  8. Migliorino, Maria R.San Camillo Forlanini Hosp, Rome, Italy
  9. Lee, Yong ChulJeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Res Ctr Pulm Dis, Dept Internal Med,Biomed Res Inst,Med Sch, Jeonju, South Korea
  10. Girard, NicolasInst Thorax Curie Montsouris, Inst Curie, Paris, France
  11. Daoud, HasanBoehringer Ingelheim Int GmbH, Ingelheim, Germany
  12. Marten, AngelaBoehringer Ingelheim Int GmbH, Ingelheim, Germany
  13. Miura, SatoruNiigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

Abstract

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be defined. Overall survival (OS) is influenced by the availability/use of subsequent therapy after first-line treatment. Emergence of T790M is the main mechanism of resistance to afatinib and second-line osimertinib could be a treatment option in this instance. Methods: In this non-interventional, global study (NCT04179890), existing medical/electronic records were identified for consecutive EGFR TKI-naive patients with EGFR mutation-positive NSCLC (Del19 or L858R) treated with first-line afatinib and second-line osimertinib in regular clinical practice (n = 191; all T790M-positive). The primary objective was time to treatment failure (TTF). Key secondary objectives were OS and objective response rate (ORR). Results: At the start of afatinib treatment, median age (range) was 62 years (34-88). Fifty-five percent of patients were female and 67% were Asian. ECOG PS (0/1/>= 2) was 31%/57%/12%. Fourteen percent of patients had brain metastases. At the start of osimertinib treatment, ECOG PS (0/1/>= 2) was 25%/61%/14% and 14% had brain metastases (rising to 29% at the end of osimertinib treatment). The source of biopsy material (solid/liquid) was 86%/3% at the start of afatinib and 54%/33% at start of osimertinib. Mutations were mainly detected with PCR methods. Overall, median TTF was 27.7 months (95% CI: 24.0-30.2) and median OS was 36.5 months (95% CI: 32.9-41.8). ORR with afatinib and osimertinib was 74% and 45%. TTF, OS and ORR were generally consistent across subgroups. Conclusion: Sequential afatinib and osimertinib demonstrated encouraging activity in patients with EGFR mutation-positive NSCLC and acquired T790M. Activity was observed across all subgroups, including patients with poor ECOG PS or brain metastases. ECOG PS and incidence of brain metastases remained stable prior to, and after, afatinib treatment.

Keywords

EGFRAfatinibOsimertinibSequentialT790MCELL LUNG-CANCER1ST-LINE TREATMENTOPEN-LABELGEFITINIB

Identifiers

Scopus EID
2-s2.0-85116862060
WoS UID
000708647200002